These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 8953047

  • 21. Role of inhibitor aliphatic chain in the thermodynamics of inhibitor binding to Escherichia coli enoyl-ACP reductase and the Phe203Leu mutant: a proposed mechanism for drug resistance.
    Protasevich II, Brouillette CG, Snow ME, Dunham S, Rubin JR, Gogliotti R, Siegel K.
    Biochemistry; 2004 Oct 26; 43(42):13380-9. PubMed ID: 15491144
    [Abstract] [Full Text] [Related]

  • 22. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis.
    Dessen A, Quémard A, Blanchard JS, Jacobs WR, Sacchettini JC.
    Science; 1995 Mar 17; 267(5204):1638-41. PubMed ID: 7886450
    [Abstract] [Full Text] [Related]

  • 23. Identification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductase.
    Ling LL, Xian J, Ali S, Geng B, Fan J, Mills DM, Arvanites AC, Orgueira H, Ashwell MA, Carmel G, Xiang Y, Moir DT.
    Antimicrob Agents Chemother; 2004 May 17; 48(5):1541-7. PubMed ID: 15105103
    [Abstract] [Full Text] [Related]

  • 24. Crystallographic insights into the structure-activity relationships of diazaborine enoyl-ACP reductase inhibitors.
    Jordan CA, Sandoval BA, Serobyan MV, Gilling DH, Groziak MP, Xu HH, Vey JL.
    Acta Crystallogr F Struct Biol Commun; 2015 Dec 17; 71(Pt 12):1521-30. PubMed ID: 26625295
    [Abstract] [Full Text] [Related]

  • 25. Protein EnvM is the NADH-dependent enoyl-ACP reductase (FabI) of Escherichia coli.
    Bergler H, Wallner P, Ebeling A, Leitinger B, Fuchsbichler S, Aschauer H, Kollenz G, Högenauer G, Turnowsky F.
    J Biol Chem; 1994 Feb 25; 269(8):5493-6. PubMed ID: 8119879
    [Abstract] [Full Text] [Related]

  • 26. The reductase steps of the type II fatty acid synthase as antimicrobial targets.
    Zhang YM, Lu YJ, Rock CO.
    Lipids; 2004 Nov 25; 39(11):1055-60. PubMed ID: 15726819
    [Abstract] [Full Text] [Related]

  • 27. Kinetic determinants of the interaction of enoyl-ACP reductase from Plasmodium falciparum with its substrates and inhibitors.
    Kapoor M, Dar MJ, Surolia A, Surolia N.
    Biochem Biophys Res Commun; 2001 Dec 14; 289(4):832-7. PubMed ID: 11735121
    [Abstract] [Full Text] [Related]

  • 28. Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay.
    Afanador GA, Muench SP, McPhillie M, Fomovska A, Schön A, Zhou Y, Cheng G, Stec J, Freundlich JS, Shieh HM, Anderson JW, Jacobus DP, Fidock DA, Kozikowski AP, Fishwick CW, Rice DW, Freire E, McLeod R, Prigge ST.
    Biochemistry; 2013 Dec 23; 52(51):9155-66. PubMed ID: 24295325
    [Abstract] [Full Text] [Related]

  • 29. Escherichia coli enoyl-acyl carrier protein reductase (FabI) supports efficient operation of a functional reversal of β-oxidation cycle.
    Vick JE, Clomburg JM, Blankschien MD, Chou A, Kim S, Gonzalez R.
    Appl Environ Microbiol; 2015 Feb 23; 81(4):1406-16. PubMed ID: 25527535
    [Abstract] [Full Text] [Related]

  • 30. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
    He X, Alian A, Ortiz de Montellano PR.
    Bioorg Med Chem; 2007 Nov 01; 15(21):6649-58. PubMed ID: 17723305
    [Abstract] [Full Text] [Related]

  • 31. Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues.
    Sivaraman S, Sullivan TJ, Johnson F, Novichenok P, Cui G, Simmerling C, Tonge PJ.
    J Med Chem; 2004 Jan 29; 47(3):509-18. PubMed ID: 14736233
    [Abstract] [Full Text] [Related]

  • 32. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
    Lu H, Tonge PJ.
    Acc Chem Res; 2008 Jan 29; 41(1):11-20. PubMed ID: 18193820
    [Abstract] [Full Text] [Related]

  • 33. Molecular dynamics simulation studies of the wild-type, I21V, and I16T mutants of isoniazid-resistant Mycobacterium tuberculosis enoyl reductase (InhA) in complex with NADH: toward the understanding of NADH-InhA different affinities.
    Schroeder EK, Basso LA, Santos DS, de Souza ON.
    Biophys J; 2005 Aug 29; 89(2):876-84. PubMed ID: 15908576
    [Abstract] [Full Text] [Related]

  • 34. Characterization of a novel enoyl-acyl carrier protein reductase of diazaborine-resistant Rhodobacter sphaeroides mutant.
    Lee IH, Kim EJ, Cho YH, Lee JK.
    Biochem Biophys Res Commun; 2002 Dec 13; 299(4):621-7. PubMed ID: 12459184
    [Abstract] [Full Text] [Related]

  • 35. Crystallization and preliminary X-ray crystallographic analysis of enoyl-acyl carrier protein reductase from Helicobacter pylori.
    Lee HH, Yun J, Moon J, Han BW, Lee BI, Lee JY, Suh SW.
    Acta Crystallogr D Biol Crystallogr; 2002 Jun 13; 58(Pt 6 Pt 2):1071-3. PubMed ID: 12037321
    [Abstract] [Full Text] [Related]

  • 36. Enoyl acyl carrier protein reductase inhibitors: a patent review (2006 - 2010).
    Lu X, Huang K, You Q.
    Expert Opin Ther Pat; 2011 Jul 13; 21(7):1007-22. PubMed ID: 21651455
    [Abstract] [Full Text] [Related]

  • 37. High-resolution structures of Thermus thermophilus enoyl-acyl carrier protein reductase in the apo form, in complex with NAD+ and in complex with NAD+ and triclosan.
    Otero JM, Noël AJ, Guardado-Calvo P, Llamas-Saiz AL, Wende W, Schierling B, Pingoud A, van Raaij MJ.
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2012 Oct 01; 68(Pt 10):1139-48. PubMed ID: 23027736
    [Abstract] [Full Text] [Related]

  • 38. Synthesis, biological evaluation and in silico molecular modeling of pyrrolyl benzohydrazide derivatives as enoyl ACP reductase inhibitors.
    Joshi SD, Dixit SR, Kulkarni VH, Lherbet C, Nadagouda MN, Aminabhavi TM.
    Eur J Med Chem; 2017 Jan 27; 126():286-297. PubMed ID: 27889632
    [Abstract] [Full Text] [Related]

  • 39. Rational optimization of drug-target residence time: insights from inhibitor binding to the Staphylococcus aureus FabI enzyme-product complex.
    Chang A, Schiebel J, Yu W, Bommineni GR, Pan P, Baxter MV, Khanna A, Sotriffer CA, Kisker C, Tonge PJ.
    Biochemistry; 2013 Jun 18; 52(24):4217-28. PubMed ID: 23697754
    [Abstract] [Full Text] [Related]

  • 40. Structural basis for the variation in triclosan affinity to enoyl reductases.
    Pidugu LS, Kapoor M, Surolia N, Surolia A, Suguna K.
    J Mol Biol; 2004 Oct 08; 343(1):147-55. PubMed ID: 15381426
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.